Skip to main content
Premium Trial:

Request an Annual Quote

Vicki Sato, Ambion

Premium

People

Bristol-Myers Squibb said this week that it has appointed Vicki Sato to its board of directors.

Sato also sits on the board of Alnylam Pharmaceuticals.

Sato is currently a professor of molecular and cell biology at Harvard University, and previously served as president of Vertex Pharmaceuticals. Prior to this, she was vice president of research at Biogen, a biotechnology firm co-founded by Alnylam co-founder Phillip Sharp.

Products & Services

Ambion recently introduced its mirVana miRNA bioarrays V2, a version of the company's microRNA microarrays that includes probes targeting an exclusive set of 152 newly identified human miRNAs.

The new bioarrays also feature 22 control probes, the company said.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.